SCHEMBL6401156

SCHEMBL6401156

OCC1CCN(c2nnc(-c3ccc(F)c(F)c3Nc3ccc(I)cc3F)o2)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 19/20 0.42
MAP2K2 P36507 18/20 0.42
BRD4 O60885 1/20 0.37
BRAF P15056 2/20 0.36
MAPK1 P28482 1/20 0.36
MAP2K5 Q13163 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
DRD1 P21728 1/20 0.36
TBXA2R P21731 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADRA1A P35348 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36
ACTR3 P61158 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6187710 0.93 MAP2K1 (0.41) MAP2K1MAP2K2BRD4BRAFMAPK1
SCHEMBL6406131 0.90 MAP2K1 (0.47) MAP2K1MAP2K2BRD4BRAFCHRM2
SCHEMBL6401090 0.86 MAP2K1 (0.48) MAP2K1MAP2K2BRD4BRAFCHRM2
SCHEMBL6206494 0.82 MAP2K2 (0.38) MAP2K1MAP2K2BRAFCHRM2CHRM1
SCHEMBL6398237 0.82 MAP2K2 (0.46) MAP2K1MAP2K2KCNH2
SCHEMBL6207744 0.80 KCNH2 (0.41) MAP2K1MAP2K2BRAFMAPK1MAP2K5
SCHEMBL6398408 0.78 MAP2K1 (0.41) MAP2K1MAP2K2BRAFCHRM2CHRM1
SCHEMBL6207211 0.76 BCHE (0.37) MAP2K1MAP2K2
SCHEMBL6208052 0.75 HRH3 (0.34) KCNH2
SCHEMBL6208327 0.74 MAP2K1 (0.52) MAP2K1MAP2K2BRAFMAPK1MAP2K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 MAP2K1 46/4885MAP2K2 40/4885BRD4 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.